ReviewCancer medicine2015
Pancreatic cancer and FOLFIRINOX: a new era and new questions.
Review in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02648711 (Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review.Future oncology (London, England) · 2025Pooled it
- The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.Cancer communications (London, England) · 2019Trial
- Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.Journal of surgical oncology · 2018Trial
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.British journal of cancer · 2016Trial
- Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Leukemia · 2016Trial
- NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design.Future oncology (London, England) · 2025Article
- Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use.Current oncology (Toronto, Ont.) · 2025Article
- Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma.Journal of health economics and outcomes research · 2025Article
- Nanoparticle-based immunotherapy of pancreatic cancer.Frontiers in molecular biosciences · 2022Review
- Irinotecan Induces Disease Remission in Xenograft Mouse Models of PediatricBiomedicines · 2021Article
- Article
- Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer.Scientific reports · 2021Article
- Immunological combination treatment holds the key to improving survival in pancreatic cancer.Journal of cancer research and clinical oncology · 2020Review
- Robotic pancreaticoduodenectomy may offer improved oncologic outcomes over open surgery: a propensity-matched single-institution study.Surgical endoscopy · 2020Article
- Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer.The Journal of pharmacology and experimental therapeutics · 2019Review
- Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.International journal of clinical oncology · 2019Article
- Article
- Use of Video Review to Investigate Technical Factors That May Be Associated With Delayed Gastric Emptying After Pancreaticoduodenectomy.JAMA surgery · 2018Observational
- Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer.Oncotarget · 2018Article
- Predictive approaches for drug combination discovery in cancer.Briefings in bioinformatics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FOLFIRINOX (FFX) was introduced to clinical practice in 2010 following publication of the PRODIGE 4/ACCORD 11 study, which compared this novel regimen to gemcitabine in metastatic pancreatic cancer. Median overall survival, progression-free survival, and objective responses were all superior with FFX and there was improved time to definitive deterioration in quality of life. Despite initial concerns over toxicity, there has been rapid uptake of this regimen, both revolutionizing management and opening the door to innovative research. As experience with FFX has accrued, many questions have arisen including the management of toxicities, the impact of frequent modifications, the optimal number of cycles, integration with other regimens and modalities, interpretation of radiologic and serologic response, utility of molecular signatures, and potential benefit in unique clinical settings such as pre- and postsurgery. This review will closely examine these issues, not only to summarize current knowledge but also to fuel scientific debate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.